NGM Biopharmaceuticals, Inc.

NasdaqGS:NGM Stock Report

Market Cap: US$128.5m

NGM Biopharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of NGM?
Owner TypeNumber of SharesOwnership Percentage
Private Companies11,6820.014%
General Public4,489,6585.38%
Public Companies12,955,01615.5%
VC/PE Firms20,285,50524.3%
Individual Insiders21,323,83725.5%
Institutions24,396,71029.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 89.91% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
24.3%
The Column Group, LLC
20,285,505US$31.2m11.9%15.17%
19.9%
David Goeddel
16,579,824US$25.5m5,010%no data
15.5%
Merck & Co., Inc.
12,955,016US$20.0m0%no data
3.81%
BlackRock, Inc.
3,178,165US$4.9m-17.2%no data
3.32%
William Rieflin
2,774,340US$4.3m0%no data
3.32%
The Vanguard Group, Inc.
2,770,574US$4.3m0.34%no data
2.86%
EcoR1 Capital, LLC
2,385,873US$3.7m-62.9%0.1%
1.89%
StepStone Group LP
1,573,357US$2.4m0%0.52%
1.6%
Acadian Asset Management LLC
1,339,331US$2.1m12.2%0.01%
1.56%
Ponoi Capital
1,298,908US$2.0m0%100.0%
1.51%
Millennium Management LLC
1,262,395US$1.9m498%no data
1.36%
Jin-Long Chen
1,133,893US$1.7m0%no data
1.19%
Euclidean Capital LLC
992,168US$1.5m0%0.16%
1.1%
Geode Capital Management, LLC
921,610US$1.4m3.91%no data
0.99%
State Street Global Advisors, Inc.
822,399US$1.3m3.51%no data
0.91%
Renaissance Technologies LLC
756,892US$1.2m44.9%no data
0.75%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
623,345US$960.0k0%no data
0.7%
Two Sigma Advisers, LP
586,900US$903.8k23.8%no data
0.67%
Jacobs Levy Equity Management Inc
555,826US$856.0k-0.5%no data
0.59%
Two Sigma Investments, LP
490,516US$755.4k20.6%no data
0.52%
Joshua Ruch
430,783US$663.4k0%no data
0.41%
Federated Hermes, Inc.
345,381US$531.9k-41%no data
0.4%
Northern Trust Global Investments
337,282US$519.4k-1.97%no data
0.4%
GSA Capital Partners LLP
334,473US$515.1k56.5%0.04%
0.37%
D. E. Shaw & Co., L.P.
308,104US$474.5k-4.46%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/04/05 10:09
End of Day Share Price 2024/04/05 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NGM Biopharmaceuticals, Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Mayank MamtaniB. Riley Securities, Inc.
Paul ChoiGoldman Sachs